US FDA Advisory Committee Freeze Raises Concerns Of Delayed, More Controversial Approvals

HHS communications restrictions are keeping the FDA from publicly scheduling expected advisory committee meetings. The lack of upcoming meetings is raising concern about missed user fee dates or lower-quality agency decision-making.